Literature DB >> 15606893

Characterization of an allosteric citalopram-binding site at the serotonin transporter.

Fenghua Chen1, Mads Breum Larsen, Henrik Amtoft Neubauer, Connie Sánchez, Per Plenge, Ove Wiborg.   

Abstract

The serotonin transporter (SERT), which belongs to a family of sodium/chloride-dependent transporters, is the major pharmacological target in the treatment of several clinical disorders, including depression and anxiety. In the present study we show that the dissociation rate, of [3H]S-citalopram from human SERT, is retarded by the presence of serotonin, as well as by several antidepressants, when present in the dissociation buffer. Dissociation of [3H]S-citalopram from SERT is most potently inhibited by S-citalopram followed by R-citalopram, sertraline, serotonin and paroxetine. EC50 values for S- and R-citalopram are 3.6 +/- 0.4 microm and 19.4 +/- 2.3 microm, respectively. Fluoxetine, venlafaxine and duloxetine have no significant effect on the dissociation of [3H]S-citalopram. Allosteric modulation of dissociation is independent of temperature, or the presence of Na+ in the dissociation buffer. Dissociation of [3H]S-citalopram from a complex with the SERT double-mutant, N208Q/N217Q, which has been suggested to be unable to self-assemble into oligomeric complexes, is retarded to an extent similar to that found with the wild-type, raising the possibility that the allosteric mechanism is mediated within a single subunit. A species-scanning mutagenesis study comparing human and bovine SERT revealed that Met180, Tyr495 and Ser513 are important residues in mediating the allosteric effect, as well as contributing to high-affinity binding at the primary site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606893     DOI: 10.1111/j.1471-4159.2004.02835.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  31 in total

1.  In vivo investigation of escitalopram's allosteric site on the serotonin transporter.

Authors:  Karen E Murray; Kerry J Ressler; Michael J Owens
Journal:  Pharmacol Biochem Behav       Date:  2015-11-24       Impact factor: 3.533

Review 2.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release.

Authors:  Joseph J Pariser; John S Partilla; Christina M Dersch; Subramaniam Ananthan; Richard B Rothman
Journal:  J Pharmacol Exp Ther       Date:  2008-04-25       Impact factor: 4.030

4.  Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram.

Authors:  Nageswari Yarravarapu; Laura Geffert; Christopher K Surratt; Michael Cascio; David J Lapinsky
Journal:  Bioorg Med Chem Lett       Date:  2018-09-22       Impact factor: 2.823

5.  Escitalopram Ameliorates Forskolin-Induced Tau Hyperphosphorylation in HEK239/tau441 Cells.

Authors:  Qing-Guo Ren; Yan-Juan Wang; Wei-Gang Gong; Qi-Da Zhou; Lin Xu; Zhi-Jun Zhang
Journal:  J Mol Neurosci       Date:  2015-02-17       Impact factor: 3.444

6.  Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound.

Authors:  Lanqiu Zhang; Mark M Rasenick
Journal:  J Pharmacol Exp Ther       Date:  2009-12-08       Impact factor: 4.030

7.  Structure-activity relationship studies of citalopram derivatives: examining substituents conferring selectivity for the allosteric site in the 5-HT transporter.

Authors:  M Andreas B Larsen; Per Plenge; Jacob Andersen; Jonas N N Eildal; Anders S Kristensen; Klaus P Bøgesø; Ulrik Gether; Kristian Strømgaard; Benny Bang-Andersen; Claus J Loland
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

8.  Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter.

Authors:  Michael J Tomlinson; Danielle Krout; Akula Bala Pramod; John R Lever; Amy Hauck Newman; L Keith Henry; Roxanne A Vaughan
Journal:  Neurochem Int       Date:  2018-08-17       Impact factor: 3.921

9.  Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.

Authors:  Ashwini K Banala; Peng Zhang; Per Plenge; George Cyriac; Theresa Kopajtic; Jonathan L Katz; Claus Juul Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2013-12-02       Impact factor: 7.446

10.  Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter.

Authors:  Per Plenge; Lei Shi; Thijs Beuming; Jerez Te; Amy Hauck Newman; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.